The Hemophilia A and B Asia-Pacific market will be valued at $699.1m and $112.9m respectively in 2022, growing from $444.9m and $76.3m in 2015, at CAGR of 6.7% and 5.8%

Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four times as common as hemophilia B, and more than half of patients with hemophilia A have a severe form of hemophilia. Males have a much higher chance of developing hemophilia because they only receive one copy of the X chromosome from their mother. To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=879379
http://www.researchmoz.us/hemophilia-a-and-b-therapeutics-in-asiapacific-markets-to-2022-growth-driven-by-increasing-treatmentreceiving-pool-launch-of-longacting-replacement-therapies-and-nonfactor-therapy-report.html